Know Your Vaccine Rights

APIAHF and the National Asian Pacific American Bar Association (NAPABA) have created fact cards for those who may be unsure of their rights to a COVID-19 vaccination. Translated into 26 different AA and NH/PI languages, this resource educates community members on the benefits of getting vaccinated and encourages them to receive their free COVID-19 vaccinations regardless of immigration status, health insurance coverage, and/or Social Security identification.

This resource is supported by the Centers for Disease Control and Prevention of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $5,117,633 with 100 percent funded by CDC/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CDC/HHS, or the U.S. Government.

English Vaccine Rights Card

Asian American Language Cards

Native Hawaiian and Pacific Islander

Language Cards

July 27, 2021

Today, the Centers for Disease Control and Prevention (CDC) updated information for fully vaccinated people given new evidence on the B.1.617.2 (Delta) variant currently circulating in the United States. The new guidance recommends:

  • Fully vaccinated people to wear a mask in public indoor settings in areas of substantial or high transmission. To determine your county's level of transmission, please visit the CDC COVID Data Tracker here

  • Universal indoor masking for all teachers, staff, students, and visitors to schools, regardless of vaccination status. 

For a full summary of changes to the CDC Interim Public Health Recommendations for Fully Vaccinated People, please visit:

July 13, 2021

FDA put out a statement on their website this afternoon. Here is what is known so far:

  • Based on an analysis of Vaccine Adverse Event Reporting (VAERS) data, there have been 100 preliminary reports of GBS following vaccination with the Johnson & Johnson (Janssen) COVID vaccine after approximately 12.5 million doses administered in the U.S.

    • Of these 100 reports of GBS, 95 of them were serious and required hospitalization. There was one reported death.

    • Although the available evidence suggests an association between the Johnson & Johnson vaccine and increased risk of GBS, it is insufficient to establish a causal relationship.

    • The FDA has evaluated the available data for the Johnson & Johnson COVID-19 Vaccine and continues to find the known and potential benefits clearly outweigh the known and potential risks.

    • No similar safety signal has been identified with the Moderna and Pfizer-BioNTech COVID-19 vaccines.

    • FDA continues to work with CDC to monitor reports of GBS following vaccination with the Johnson & Johnson COVID-19 Vaccine.

  • Each year in the United States, an estimated 3,000 to 6,000 people develop GBS. Most people fully recover from the disorder.

  • GBS has also been observed at an increased rate associated with certain vaccines, including certain seasonal influenza vaccines and the vaccine to prevent shingles (Zoster vaccine).   

The updated versions of the J&J COVID-19 Vaccine Fact Sheets are available on the FDA website:

May 13, 2021

CDC updated the Interim Public Health Recommendations for Fully Vaccinated People  to advise that fully vaccinated people no longer need to wear a mask or physically distance in any setting, except where required by federal, state, local, tribal, or territorial laws, rules, and regulations, including hospitals, nursing homes, schools, and any regulatory requirements of local business and workplace guidance.  The Interim Public Health Recommendations for Fully Vaccinated People do not apply to healthcare settings. This means that staff, patients, residents and visitors should continue to wear masks as recommended in all healthcare facilities.


Healthcare facilities should continue to refer to the Updated Healthcare Infection Prevention and Control Recommendations in Response to COVID-19 Vaccination for recommendations regarding source control and physical distancing in healthcare settings.  CDC is considering how or if the updates for the community should be applied in healthcare and will update the healthcare guidance accordingly.  We will keep you informed if any changes are made to the guidance for healthcare settings.

May 12, 2021

The Advisory Committee of Immunization Practices (ACIP) affirmed the FDA’s authorization of Pfizer’s vaccine to children, ages 12-15. Its recommendation means that pediatricians and family physicians can begin administering the vaccine immediately.

To address questions about vaccines and misinformation, below are new informational tools, resources, and key points developed by CDC to support educational efforts.

  • New web page: COVID-19 Vaccines for Children and Teens provides information about the benefits of COVID-19 vaccines for adolescents aged 12 and older, how to find a vaccination provider for adolescents, and what to expect during and after vaccination. 

  • New fact sheet: COVID-19 Vaccines for Preteens and Teens  is a printable fact sheet for parents that explains the benefits of a COVID-19 vaccine for their children, safety information, and what to expect during and after vaccination. 

  • New frequently asked questions: Two new FAQs  address questions about the safety and benefits of COVID-19 vaccination for adolescents aged 12 and older. 

  • Myth-buster about infertility: It is safe for people who would like to have a baby one day to get a COVID-19 vaccine. This question and answer explains why. 

  • Key things to know: The web pages Key Things to Know about COVID-19 Vaccines and About COVID-19 Vaccines have been updated to include the recommendation that adolescents aged 12 and older get vaccinated. 


Information for Healthcare and Vaccine Providers:

  • New pediatric toolkit: The Pediatric Healthcare Professionals COVID-19 Vaccination Toolkit provides materials to help healthcare providers give parents clear and accurate information about COVID-19 vaccines. The toolkit includes answers to common questions, an explanation of how mRNA vaccines work, and printable materials to give to parents. 

  • New FAQs about consent for minors: FAQs have been posted on the Pfizer-BioNTech product page for providers with information about consent,  prescreening questions, and other issues related to the vaccination of minors.   


Information for Community Groups:

April 23, 2021

From our partners at Morehouse School of Medicine National COVID-19 Resiliency Network

The U.S. Food and Drug Administration (FDA) and the U.S. Centers for Disease Control and Prevention (CDC) released a joint statement regarding their determination that the recommended pause regarding the use of the Janssen (Johnson & Johnson) COVID-19 vaccine should resume.


The statement follows the April 13, 2021 joint CDC and FDA  that highlighted six cases of a rare and severe type of blood clot and low platelets, also known as thrombosis-thrombocytopenia syndrome (TTS) following administration of the Janssen COVID-19 Vaccine. 


Key Facts:

  1. As of April 13, more than 6.8 million of the Janssen (Johnson & Johnson) COVID-19 Vaccine doses had been administered in the United States.

  2. Today, the FDA and CDC confirmed that a total of 15 cases of TTS have been reported to the Vaccine Adverse Event Reporting System (VAERS).

    • These cases include the original six reported cases from April 13, 2021, joint CDC and FDA statement.

    • All of these cases occurred in women between the ages of 18 and 59, with a median age of 37 years, indicating symptom onset between 6 and 15 days after vaccination.

  3. Community members should report adverse events following vaccination to the Vaccine Adverse Event Reporting System (VAERS).

Learn more: